ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

NCI Ponders Options for Implementing NCAB Changes In Organ Site Program

June 4, 1982

“Evolving Concept” Looks At Appropriate Early Decision Making In Patient Management

September 28, 1984

Data Falsification Charge To Be Aired

June 27, 1980

How NCI Plans to Spend the $3 Billion Budget; But First, A Caveat From the Director

November 19, 1999

Tarceva Reaches Endpoint Early: Longer PFS Than Chemo Alone

February 25, 2011

ODAC Member Critical Of Amgen For Price Incentives.

March 21, 2008